tiotropium 2.5mcg respimat inhaler (Spiriva-Respimat®) No. (411/07)
Boehringer Ingelheim Ltd

Product Update

9 November 2007

The Scottish Medicines Consortium has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

**ADVICE:** following an abbreviated submission

**tiotropium respimat inhaler (Spiriva Respimat®)** is accepted for restricted use within NHS Scotland as maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease.

It may be used for patients in whom tiotropium is an appropriate choice of maintenance bronchodilator treatment but it is restricted to patients who have poor manual dexterity and therefore have difficulty using the Handihaler device.

**Advice context:**

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 2 November 2007.

Chairman,
Scottish Medicines Consortium